Influence of Genetic Polymorphisms of Cytochrome P450 1A2, 2D6 and Dopamine Receptor D2 on the Reduction Rate of PANSS Score of Olanzapine Treatment for Schizophrenia

OBJECTIVE To explore the influence of genetic polymorphisms of cytochrome P450(CYP) 1A2, 2D6 and dopamine receptor D2(DRD2) on the reduction rate of positive and negative syndrome scale(PANSS) score of olanzapine treatment for schizophrenia. METHODS One hundred seventy eight cases of schizophrenia inpatients treated with olanzapine were recruited. PANSS were evaluated at baseline and 4 weeks after olanzapine treatment. The PANSS total score reduction rates were calculated. Meanwhile, their blood was collected for genetic polymorphism detections of CYP1A2*1F, CYP2D6*10, DRD2-141C Ins/Del, DRD2-241 A>G and DRD2 Taq1A. The difference of PANSS score reduction rates among genotypes in each gene were compared by analysis of variance, and its regression equation was obtained by multivariate linear regression analysis. RESULTS The PANSS reduction rates among genotypes in CYP1A2*1F(CC:65.68±11.22, CA:55.59±15.40, AA:43.75±15.20), CYP2D6*10(CC:44.36±16.67; CT:51.78±17.81; TT:56.14±17.13), DRD2-141C Ins/Del(Ins/Ins:55.11±17.39, Ins/Del:39.16±14.28) and DRD2-241 A>G (AA:45.47±17.52; GA:61.82±10.55; GG:75.43±17.71) were obviously different(all P<0.01). However, the reduction rates in DRD2 Taq1A genotypes did not show a significant change(P>0.05). PANSS reduction rate=58.041-10.703×CYP1A2*1F+4.272×CYP2D6*10-11.921×DRD2-141C Ins/Del+13.443×DRD2-241A>G(R²=0.517, P<0.05). CONCLUSION Genetic polymorphisms of CYP1A2*1F, CYP2D6*10, DRD2-141 C Ins/Del, and DRD2-241A>G can influence efficacy of olanzapine treatment for schizophrenia patients, but they only accounted for 51.7% of the reduction. More influencing factors are needed to be included for analysis.